MedPath

Sumitomo Pharma America, Inc.

Sumitomo Pharma America, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
1984-01-01
Employees
5K
Market Cap
-
Website
http://www.sunovion.com

Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability

Phase 3
Completed
Conditions
Primary Insomnia
Interventions
Drug: Placebo
First Posted Date
2006-08-24
Last Posted Date
2012-02-22
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
32
Registration Number
NCT00368056
Locations
🇬🇧

HPRU Medical Research Centre, University of Surrey, Guildford, Surrey, United Kingdom

Study of Eszopiclone Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause/Menopause

Phase 3
Completed
Conditions
Insomnia
Interventions
Drug: Placebo
First Posted Date
2006-08-18
Last Posted Date
2012-02-22
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
410
Registration Number
NCT00366093

Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Other: Sugar Pill
First Posted Date
2006-08-03
Last Posted Date
2013-07-02
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
171
Registration Number
NCT00359944
Locations
🇺🇸

PsyPharma Clinical Research Inc., Phoenix, Arizona, United States

🇺🇸

Pacific Research Network, San Diego, California, United States

🇺🇸

Research Center of Florida Inc., Miami, Florida, United States

and more 30 locations

6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia

Phase 3
Completed
Conditions
Primary Insomnia
Interventions
Drug: Placebo
First Posted Date
2006-07-14
Last Posted Date
2012-02-22
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
830
Registration Number
NCT00352144

Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB

Phase 3
Completed
Conditions
Exercise-induced Bronchospasm
Interventions
First Posted Date
2005-12-22
Last Posted Date
2012-02-22
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
15
Registration Number
NCT00268723

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Phase 3
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Emphysema
Bronchitis
Interventions
First Posted Date
2005-11-08
Last Posted Date
2012-06-04
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
443
Registration Number
NCT00250679

Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

Phase 4
Completed
Conditions
Insomnia
Generalized Anxiety Disorder
Interventions
First Posted Date
2005-10-10
Last Posted Date
2012-02-22
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
420
Registration Number
NCT00235508

A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2004-08-02
Last Posted Date
2014-04-17
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
61
Registration Number
NCT00088621
Locations
🇺🇸

Segal Institute for Clinical Research, North Miami, Florida, United States

🇺🇸

Optimum Health Services, La Mesa, California, United States

🇺🇸

Birmingham Psychiatry Pharmaceutical, Birmingham, Alabama, United States

and more 16 locations

A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2004-08-02
Last Posted Date
2016-04-08
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
180
Registration Number
NCT00088634
Locations
🇺🇸

Birmingham Psychiatry Pharmaceutical, Birmingham, Alabama, United States

🇺🇸

Summit Research Group, Little Rock, Arkansas, United States

🇺🇸

Comprehensive NeuroScience, Cerritos, California, United States

and more 19 locations

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
First Posted Date
2003-12-11
Last Posted Date
2012-02-22
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
445
Registration Number
NCT00073827
Locations
🇺🇸

Clinical Research Centers of Colorado PC, Englewood, Colorado, United States

🇺🇸

University of Maryland School of Medicine, Baltimore, Maryland, United States

🇺🇸

Princeton Center for Clinical Research, Princeton, New Jersey, United States

and more 60 locations
© Copyright 2025. All Rights Reserved by MedPath